LifeStance reports 25% revenue growth in Q3 2026 and raises full-year outlook

LifeStance Health reported a 25% increase in revenue to $455.9 million for Q3 2026, driven by higher visit volumes and clinician growth. Net income rose to $22.4 million from $1.1 million the previous year, with Adjusted EBITDA up 70% to $68.4 million. The company raised its full-year 2026 revenue guidance to $1.741-$1.761 billion, reflecting strong operational momentum and investments in technology. This growth signals LifeStance's expanding role in outpatient mental healthcare and confidence in future scaling.

Following LifeStance Health's strong Q3 2026 results and raised full-year outlook, its stock price on Pluang has gained momentum, rising 4.71% to USD 14.88 as of Nov 05, 2026 18:11 WIB. The company holds a market capitalization of $5.40 billion on the platform, with investors typically holding the stock for about 13 days. This trading activity highlights continued investor interest in LifeStance's growth story.